Background: This session focuses on current evidence for the role of bacterial vaginosis (BV) in HIV acquisition and transmission and based on this how future research on the vaginal microbiome may help to inform HIV prevention interventions. Our understanding of normal and abnormal vaginal flora including BV has undergone radical shifts during the past decade. While our thinking about BV continues to evolve it is best understood as a polymicrobial condition in which the lactobacilli species which dominate vaginal flora under normal conditions are replaced by diverse populations of anaerobic and facultative anaerobic organisms. Evidence points to the role of predisposing host factors including hormonal and immunological parameters in facilitating BV occurrence and persistence. BV is consistently associated with high risk sexual behaviours such as multiple partners and lack of condom use. However a specific sexual aetiology of BV remains elusive. Several prospective studies have found that the presence of BV or abnormal vaginal flora in HIV-negative women appears associated with increased risk of HIV acquisition. This evidence is summarized in recent meta-analyses finding an increased risk of HIV infection in women with BV compared to women with normal vaginal flora independent of measured sexual risk behaviours (hazard ratio 1.69; 95% confidence intervals 1.36-2.10). A range of mechanisms have been posited to explain this association. However the absence of a clear mechanistic model for vaginal HIV acquisition coupled with well-documented challenges in adjustment for covariation in sexual risk behaviours limit insights from existing epidemiological data. Also BV occurs more commonly in women infected with HIV and recently a groundbreaking study of serodiscordant partnerships demonstrated that BV was associated with increased risk of female-to-male HIV transmission; this finding is supported by studies showing increased shedding of HIV in the vagina under conditions of BV. Conclusions: Given the available evidence strategies to treat BV for HIV prevention are of clear interest. Yet the effective treatment of BV is notoriously challenging with recurrence commonly observed following existing therapies in many women. Altogether it seems unlikely that additional epidemiologic studies investigating the association between BV and HIV acquisition or intervention trials using existing treatment modalities will yield significant new advances in HIV prevention. More productive new directions are likely to result from either more specific microbiologic definitions of BV that can be applied in studies of BV prevention and/or more clearly defined mechanisms of female HIV acquisition that may be related to the vaginal microbiome.